Dr. Javier Luis Munoz, FACP, MD, MS

Dr. Munoz practices at Mayo Clinic Hospital - Phoenix in Phoenix, Arizona, part of Mayo Clinic.

Dr. Munoz's NPI, 1083823637, was assigned on May 21, 2007. Dr. Munoz graduated from Cayetano Heredia University in 2004. Dr. Munoz holds Arizona license 46881.

Dr. Munoz's primary practice is Mayo Clinic Hospital - Phoenix, at 5777 East Mayo Boulevard, Phoenix, AZ 85054 in Maricopa County. The practice phone is (480) 342-4201.

Dr. Munoz's primary practice is Mayo Clinic Hospital - Phoenix in Phoenix, Arizona, part of Mayo Clinic. The medical group on file is Mayo Clinic Arizona.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Munoz practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Munoz's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Munoz is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Munoz's licenses on file in 3 states: Arizona, Texas and Michigan.

Dmand AI lists anemia, breast cancer, chronic leukemia, colorectal cancer, immune deficiency disease, lung cancer, lymphoma and multiple myeloma among the conditions Dr. Munoz treats.

CMS data shows 73,187 Medicare services from Dr. Munoz across 55 procedure codes in 2024, for 869 Medicare patients. Medicare paid $1,513,241 for them.

CMS counts 869 Medicare patients who saw Dr. Munoz in 2024. The largest group is 65 to 74, with 392 patients. 69% of them have high cholesterol, and 68% have high blood pressure. 3% are also on Medicaid. Their average risk score is 2.57, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Munoz's median patient age at 72, with 48% women.

In 2024, Dr. Munoz wrote 497 Medicare Part D claims for 92 patients. 87% of them were for generic drugs. CMS names the drug for 390 of them, across 10 drugs with 11 or more claims each, at $506,618 in total drug cost. In 2023, CMS named 230 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Munoz for performance year 2024, reported as part of a group. Dr. Munoz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Munoz as offering telehealth.

Dmand AI links 103 papers to Dr. Munoz, published from 2011 to 2025. 2022 was the busiest year, with 11. The most frequent topics are Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse and Receptors, Chimeric Antigen. Dr. Munoz has published most often in Blood. Dr. Munoz's most frequent co-authors are Yi Lin, MD, Frederick Lundry Locke, MD and David Bernard Miklos, MD, PhD.

Dmand AI links Dr. Munoz to 29 clinical trials, 10 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Lymphoma, B-Cell, Lymphoma, Non-Hodgkin and Lymphoma, Large B-Cell, Diffuse. Kite, A Gilead Company sponsors the most, 6.

CMS Open Payments shows 1,111 general payments to Dr. Munoz from 35 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 48% of the total. Kite Pharma, Inc. paid the most, $262,887. It also lists 19 research payments totaling $9,005 from 2019 to 2025.

Dmand AI lists 9 awards for Dr. Munoz, most recently ASH Hematology Opportunities for the Next-generation of Research Scientists HONORS Award (Mentor) in 2019.

Dr. Munoz graduated from Cayetano Heredia University in 2004.

Dr. Munoz is in network with 8 carriers, including Elevance, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 5. Check the plan with the practice before a visit.